Selected article for: "healthcare utilization and significant morbidity"

Author: Ishigami, Junichi; Kou, Minghao; Ding, Ning; Matsushita, Kunihiro
Title: Cardiovascular Disease and Coronavirus Disease 2019: Epidemiology, Management, and Prevention
  • Cord-id: w4g73jgv
  • Document date: 2021_1_2
  • ID: w4g73jgv
    Snippet: PURPOSE OF REVIEW: Coronavirus disease 2019 (COVID-19) has become a global pandemic associated with significant morbidity and mortality. This review summarizes findings up to date on the relationship between cardiovascular disease (CVD) and COVID-19. RECENT FINDINGS: Preexisting CVD is a common condition among patients with COVID-19 and is associated with increased disease severity and mortality. Conversely, COVID-19 has various clinical manifestations on cardiovascular system, including thrombo
    Document: PURPOSE OF REVIEW: Coronavirus disease 2019 (COVID-19) has become a global pandemic associated with significant morbidity and mortality. This review summarizes findings up to date on the relationship between cardiovascular disease (CVD) and COVID-19. RECENT FINDINGS: Preexisting CVD is a common condition among patients with COVID-19 and is associated with increased disease severity and mortality. Conversely, COVID-19 has various clinical manifestations on cardiovascular system, including thrombotic events and cardiac dysfunction. The pandemic has impacted healthcare utilization among patients with CVD, which may have led to potential delay in access to the healthcare system during acute events not directly COVID-19-related. SUMMARY: While COVID-19 vaccine is being developed and distributed, controlling CVD risk factors and adherence to recommendations of existing immunization (e.g., influenza vaccine) are key in protecting the health of individuals with CVD during the COVID-19 pandemic. Further research is needed to understand the epidemiological and pathophysiological basis for the interaction between CVD and COVID-19.

    Search related documents:
    Co phrase search for related documents
    • acei enzyme inhibitor and low molecular weight heparin: 1
    • acei enzyme inhibitor and lung disease: 1
    • acute coronary syndrome and lombardy region: 1, 2
    • acute coronary syndrome and long term impact: 1
    • acute coronary syndrome and low molecular: 1, 2, 3, 4
    • acute coronary syndrome and low molecular weight heparin: 1, 2, 3, 4
    • adequate protection and lombardy region: 1
    • adequate protection and long term impact: 1, 2
    • lombardy region and long term impact: 1, 2
    • lombardy region and low molecular: 1, 2, 3
    • lombardy region and low molecular weight heparin: 1, 2, 3
    • long term consequence and lung disease: 1, 2, 3
    • long term impact and low molecular: 1, 2
    • long term impact and low molecular weight heparin: 1
    • long term impact and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • low molecular and lung disease: 1, 2, 3, 4, 5, 6, 7, 8
    • low molecular weight heparin and lung disease: 1, 2, 3